The Past and Future of Tuberculosis Research by Comas, Iñaki & Gagneux, Sebastien
Review
The Past and Future of Tuberculosis Research
In ˜aki Comas, Sebastien Gagneux*
Division of Mycobacterial Research, MRC National Institute for Medical Research, London, United Kingdom
Abstract: Renewed efforts in tuberculosis (TB) research
have led to important new insights into the biology and
epidemiology of this devastating disease. Yet, in the face
of the modern epidemics of HIV/AIDS, diabetes, and
multidrug resistance—all of which contribute to suscep-
tibility to TB—global control of the disease will remain a
formidable challenge for years to come. New high-
throughput genomics technologies are already contribut-
ing to studies of TB’s epidemiology, comparative geno-
mics, evolution, and host–pathogen interaction. We argue
here, however, that new multidisciplinary approaches—
especially the integration of epidemiology with systems
biology in what we call ‘‘systems epidemiology’’—will be
required to eliminate TB.
Introduction
Tuberculosis (TB) remains an important public health problem
[1]. With close to 10 million new cases per year, and a pool of two
billion latently infected individuals, control efforts are struggling in
many parts of the world (Figure 1). Nevertheless, the renewed
interest in research and improved funding for TB give reasons for
optimism. Recently, the Stop TB Partnership, a network of
concerned governments, organizations, and donors lead by the
WHO (http://www.stoptb.org/stop_tb_initiative/), outlined a
global plan to halve TB prevalence and mortality by 2015 and
eliminate the disease as a public health problem by 2050 [2].
Attaining these goals will depend on both strong government
commitment and increased interdisciplinary research and devel-
opment. As existing diagnostics, drugs, and vaccines will be
insufficient to achieve these objectives, a substantial effort in both
basic science and epidemiology will be necessary to develop better
tools and strategies to control TB [3]. Here we review the recent
history of TB research and some of the latest insights into the
evolutionary history of the disease. We then discuss ways in which
we could benefit from a more comprehensive systems approach to
control TB in the future.
Recent History of the Field
TB is caused by several species of gram-positive bacteria known
as tubercle bacilli or Mycobacterium tuberculosis complex (MTBC).
MTBC includes obligate human pathogens such as Mycobacterium
tuberculosis and Mycobacterium africanum, as well as organisms adapted
to various other species of mammal. In the developed world, TB
incidence declined steadily during the second half of the 20th
century and so funds available for research and control of TB
decreased substantially during that time [4]. When TB started to
reemerge in the early 1990s, fuelled by the growing pandemic of
HIV/AIDS (Box 1), scientists and public health officials were
caught off-guard; billions of dollars of emergency funds were
necessary to control TB outbreaks [5]. Moreover, long-term
neglect of basic TB research and product development meant that
global TB control relied on a 100-year-old diagnostic method (i.e.
sputum smear microscopy) of poor sensitivity, an 80-year-old and
largely ineffective vaccine (Bacille Calmette-Gue ´rin [BCG]), and
just a few drugs that were decades old (streptomycin, rifampicin,
isoniazid, ethambutol, pyrozinamide) [3]. Tragically, these are the
tools still in use today in most parts of the world where TB remains
one of the most important public health problems (Figure 1).
In addition to the lack of appropriate tools to control TB
globally, much about the disease was unknown in the early 1990s
and many dogmas were guiding the field at the time. These
included the view that differences in the clinical manifestation of
TB were primarily driven by host variables and the environment
as opposed to bacterial factors, a notion reinforced by early DNA
sequencing studies that reported very limited genetic diversity in
MTBC compared with other bacterial pathogens [6]. According
to other dogmas, TB was mainly a consequence of reactivation of
latent infections rather than ongoing disease transmission, and that
mixed infections and exogenous reinfections with different strains
were very unlikely.
The development of molecular techniques to differentiate
between strains of MTBC made it possible to readdress some of
these points. One of these methods, a DNA fingerprinting protocol
based on the Mycobacterium insertion sequence IS6110, quickly
evolved into the first international gold standard for genotyping of
MTBC [7]. It also became a key component of pragmatic public
health efforts, such as detecting disease outbreaks and ongoing TB
transmission [8], and allowed differentiation between patients who
relapsed due to treatment failure and those reinfected with a
different strain [9]. This latter finding demonstrated for the first
time that previous exposure to MTBC does not protect against
subsequent exogenous reinfection and TB disease, which is a
phenomenon with implications for vaccine design. Many other
new insights were gained through these molecular epidemiological
studies [10], which, for the most part, were performed in wealthy
countries; corresponding data from most high-burden areas
remained limited because of poor infrastructure and lack of
funding.
Routine genotyping of MTBC for public health purposes also
revived discussions about the role of pathogen variation in
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appeared over-represented in particular patient populations,
which suggested that strain diversity may have epidemiological
implications. The completion of the first whole genome sequence
of M. tuberculosis in 1998 [11] and the development of DNA
microarrays offered a new opportunity to address this question by
interrogating the entire genome of multiple clinical strains of
MTBC. These comparative genomics studies revealed that
genomic deletions, also known as large sequence polymorphisms
(LSPs), are an important source of genome plasticity in MTBC
[12]. Furthermore, statistical analyses of patient data suggested
possible associations between strain genomic content and disease
severity in humans [13]. Clinical phenotypes in TB are difficult to
standardize, however, and whether MTBC genotype plays a
meaningful role in TB severity remains controversial [14].
Comparative genomics of MTBC also yielded interesting insights
into the evolution and geographic distribution of the organism.
Because MTBC has essentially no detectible horizontal gene transfer
[15,16], LSPs can be used as phylogenetic markers to trace the
evolutionary relationships of different strain families. Following such
an approach, studies have shown that humans did not, as previously
believed, acquire MTBC from animals during the initiation of animal
domestication, rather the human- and animal-adapted members of
MTBC share a common ancestor, which might have infected humans
even before the Neolithic transition [17,18]. LSPs also allowed
researchers to define several discrete strain lineages within the human-
adapted members of MTBC, which are associated with different
human populations and geographical regions (Figures 2 and 3)
[15,19,20]. Because of the lack of horizontal gene exchange in
MTBC, phylogenetic trees derived using various molecular markers
define the same phylogenetic groupings [21], and several studies based
on single nucleotide polymorphisms (SNPs) and other molecular
makers have gathered additional support for the highly phylogeo-
graphical population structure of MTBC [22–25].
Ancient History of the Pathogen
Although LSPs have proven very useful for defining different
lineages within MTBC, these markers do not reflect actual genetic
distances, and the mode of molecular evolution in MTBC cannot
be easily inferred from them [21]. By contrast, DNA sequence-
based methods can provide important clues about the evolutionary
forces shaping bacterial populations. Multilocus sequence typing
(MLST), in which fragments of seven structural genes are
Figure 1. The global incidence of TB. The number of new TB cases per 100,000 population for the year 2007 according to WHO estimates
(adapted from [1]).
doi:10.1371/journal.ppat.1000600.g001
Box 1. The Influence of Modern Epidemics on
TB Incidence
HIV/AIDS and diabetes are important comorbidities that
dramatically increase the susceptibility to TB. The synergy
between TB and HIV/AIDS is a particular problem in sub-
Saharan Africa, while the impact of diabetes on TB is
increasing in many rapidly growing world economies; it
may already be a more important risk factor for TB than
HIV/AIDS in places like India and Mexico. The emergence
of multidrug-resistant strains represents an additional
threat to global TB control. The strong association
between HIV/AIDS and drug-resistant TB has been well
established, but whether similar interactions exist between
drug-resistant TB and diabetes needs to be explored
further.
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define the genetic population structure of many bacterial species
[27]. Because of the low degree of sequence polymorphisms in
MTBC, however, standard MLST is uninformative [28]. A recent
study of MTBC extended the traditional MLST scheme by
sequencing 89 complete genes in 108 strains, covering 1.5% of the
genome of each strain [29]. Phylogenetic analysis of this extended
multilocus sequence dataset resulted in a tree that was highly
congruent with that generated previously using LSPs (Figure 3).
The new sequence-based data also revealed that the MTBC
strains that are adapted to various animal species represent just a
subset of the global genetic diversity of MTBC that affects different
human populations [29]. Furthermore, by comparing the
geographical distribution of various human MTBC strains with
their position on the phylogenetic tree, it became evident that
MTBC most likely originated in Africa and that human MTBC
originally spread out of Africa together with ancient human
migrations along land routes. This view is further supported by the
fact that the so-called ‘‘smooth tubercle bacilli,’’ which are the
closest relatives of the human MTBC, are highly restricted to East
Africa [30]. The multilocus sequence data reported by Hershberg
et al. [29] further suggested a scenario in which the three
‘‘modern’’ lineages of MTBC (purple, blue, and red in Figure 3)
seeded Eurasia, which experienced dramatic human population
expansion in more recent times. These three lineages then spread
globally out of Europe, India, and China, respectively, accompa-
nying waves of colonization, trade and conquest. In contrast to the
ancient human migrations, however, this more recent dispersal of
human MTBC occurred primarily along water routes [29].
The availability of comprehensive DNA sequence data has also
allowed researchers to address questions about the molecular
evolution of MTBC. In-depth population genetic analyses by
Hershberg et al. highlight the fact that purifying selection against
slightly deleterious mutations in this organism is strongly reduced
compared to other bacteria [29]. As a consequence, nonsynon-
ymous SNPs tend to accumulate in MTBC, leading to a high ratio
of nonsynonymous to synonymous mutations (also known as dN/
dS). The authors hypothesized that the high dN/dS in MTBC
compared to most other bacteria might indicate increased random
genetic drift associated with serial population bottlenecks during
past human migrations and patient-to-patient transmission. If
confirmed, this would indicate that ‘‘chance,’’ not just natural
selection, has been driving the evolution of MTBC. Although these
kinds of fundamental evolutionary questions are often underap-
preciated by clinicians and biomedical researchers, studying the
evolution of a pathogen ultimately allows for better epidemiolog-
ical predictions by contributing to our understanding of basic
biology, particularly with respect to antibiotic resistance.
A Vision for the Future
Thanks to recent increases in research funding for TB [4],
substantial progress has been made in our understanding of the
basic biology and epidemiology of the disease. Unfortunately, this
increased knowledge has not yet had any noticeable impact on the
current global trends of TB (Figure 1). While TB incidence
appears to have stabilized in many countries, the total number of
cases is still increasing as a function of global human population
growth [1]. Of particular concern are the ongoing epidemics of
multidrug-resistant TB [31], as well as the synergies between TB
and the ongoing epidemics of HIV/AIDS and other comorbidities
such as diabetes (Box 1).
Figure 2. Global distribution of the six main lineages of human MTBC. Each dot represents the most frequent lineage(s) circulating in a
country. Colours correspond to the lineages defined in Figure 3 (adapted from [20]).
doi:10.1371/journal.ppat.1000600.g002
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make better predictions about the future trajectory of the disease
and to develop new tools to control the disease better and ultimately
reverse global trends. For this to be feasible, TB epidemiology needs
to evolve into a more predictive, interdisciplinary endeavour; a
discipline we might refer to as ‘‘systems epidemiology’’ (Figure 4).
Systems biology is already a rapidly emerging field, in which cycles
of mathematical modelling and experiments using various large-
scale ‘‘-omics’’ datasets are integrated in an iterative manner [32].
Novel biological processes are being discovered through these
systemsapproaches,whichmight not havebeenpossible usingmore
traditional methods [33–35].
Last year, Young et al. argued that systems biology approaches
will be necessary to elucidate some of the key aspects of host–
pathogen interactions in TB [36] and to develop new drugs,
vaccines, and biomarkers to evaluate new interventions [3]. For
example, according to another dogma in the TB field, latent TB
infections are caused by physiologically dormant bacilli and can
thus be differentiated from active disease where MTBC is actively
growing and dividing [37]. In reality, however, the phenomenon
of TB latency most likely reflects a whole spectrum of responses to
TB infection, involving phenotypically distinct bacterial subpop-
ulations and spanning various degrees of bacterial burden and
associated host immune responses [38]. We agree with Young
et al. [36] that TB latency and similar biological complexities will
only be adequately addressed using systems approaches, and we
argue further that to comprehend the current TB epidemic as a
whole, and to better predict its future trajectory, a complementary
systems epidemiology approach will be necessary (Figure 4).
Mathematical models are already being used extensively to study
the epidemiology of TB and to guide control policies [39]. Recent
applications have shown that socioeconomic factors are key drivers
Figure 3. The global phylogeny of Mycobacterium tuberculosis complex (MTBC). The phylogenic relationships between various human- and
animal-adapted strains and species are largely consistent when defined by using either (A) large sequence polymorphisms (LSPs) or (B) single
nucleotide polymorphisms (SNPs) identified by sequencing 89 genes in 108 MTBC strains. Numbers inside the squares in (A) refer to specific lineage-
defining LSPs. Colors indicate congruent lineages (adapted from [20] and [29]).
doi:10.1371/journal.ppat.1000600.g003
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has been placed on trying to define the impact that drug resistance
will have on the global TB epidemic [41]. Some of this theoretical
work has become more complex by incorporating new biological
insights obtained empirically and through targeted experimental
studies. Early theoretical studies on the spread of drug-resistant
MTBC were based on the assumption that all drug-resistant
bacteria had an inherent fitness disadvantage compared to drug-
susceptible strains [42]; however, as is becoming clear from
experimental and molecular epidemiological investigation, substan-
tial heterogeneity exists with respect to the reproductive success of
drug-resistant strains [43–46]. Newer mathematical models account
for some of this heterogeneity [47–49].
One could imagine an expansion of such mathematical
approaches—much as systems biology operates—in which epide-
miological modelling is combined with more comprehensive
biological data related to the host, the pathogen, and their
interactions (Figure 4). Of course, environmental and sociological
data would also need to be considered [40]. As mathematical
models become more finely tuned, they could in turn inform
future experimental work to test some of the specific predictions.
The genomics revolution now offers the opportunity to study host–
pathogen interactions at an unprecedented depth. To be able to
make sense out of the current and upcoming deluge of -omics data,
however, scientists will have to rely on a mathematically and
statistically robust analytical framework. Ideally, some of these
theoretical approaches will be able to accommodate increasingly
diverse sets of data in order to capture the various biological,
environmental, and social aspects of TB.
Among the newly emerging technologies, we believe that next-
generation DNA sequencing will play an important role in
improving our understanding of TB [50]. Whole-genome
sequencing could potentially become the new gold standard for
strain typing in routine molecular epidemiology [51]. For host
genetics and TB susceptibility, too, de novo DNA sequencing
based approaches could have advantages over traditional SNP
typing [52]. For example, many of the human populations
carrying the largest proportion of the global TB burden have
not been sufficiently characterised genetically (Figure 1) [53,54],
and screening for currently limited human SNP collections might
have little relevance for these populations [55]. Furthermore,
comprehensive DNA sequencing of TB patients and controls in
various human populations could help unveil rare but biologically
relevant mutations [56]. Another approach increasingly being
Figure 4. A systems epidemiology approach to TB research. The spread of TB is influenced by social and biological factors. On the one hand,
the new discipline of systems biology integrates approaches that address the host, the pathogen, and interactions between the two. On the other
hand, epidemiology addresses the burden of the disease and the social, economic, and ecological causes of its frequency and distribution. There is
little crosstalk between these two disciplines at the moment. ‘‘Systems epidemiology’’ is an attempt to take into account the interactions between
these various fields of research.
doi:10.1371/journal.ppat.1000600.g004
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transcriptomics, in which gene expression is measured by whole
genome sequencing of RNA transcripts; a method referred to as
RNA-seq [57]. One of the advantages of this approach over
existing microarray-based methods is that changes in the
expression of noncoding RNAs and other novel transcripts can
be easily detected. RNA-seq is particularly useful for genome-wide
studies of small regulatory RNAs, as such studies are more difficult
to perform using standard DNA microarrays. Recent studies, for
example, have reported a role for small regulatory RNAs in M.
tuberculosis [58], and there is little doubt more regulatory RNAs will
soon be identified by RNA-seq [57].
Challenges for the Future
Advances in TB research are hampered by the fact that MTBC
is a Biosafety Level 3 pathogen with a long generation time,
making it slow and complex to culture. Moreover, TB is a chronic
disease that can develop over many years, and is characterised by
extended periods of latency during which MTBC cannot be
isolated from infected individuals. All of these factors complicate
and prolong the development of new interventions and their
assessment in clinical trials. As we have already mentioned, the
field has been marked by a number of dogmas that, in some cases,
might have contributed to the slow progress in TB research. New
insights are now questioning some of these views, but at the same
time, new opinions could well evolve into new dogmas. For
example, we and others have spent much of our scientific careers
seeking convincing evidence for the role of MTBC strain diversity
in human disease. Although some pieces of evidence have recently
started to emerge [59–61], the subject needs more work. One of
the problems has been that the macrophage and mouse infection
models used in these studies relied on poorly characterised strains,
and finding relevant links to human disease has been all but
impossible [14,21].
In TB control, too, potential new dogmas might emerge to limit
future progress. A strong T cell–derived interferon gamma (INFc)
response appears to be crucial for the immunological control of
TB, and many MTBC antigens have been identified based on
their capacity to elicit INFc responses in TB patients or their
infected contacts [62]. Some of these antigens are being developed
into new TB diagnostics and vaccines, but the potential impact of
MTBC diversity on immune responses is not generally being
considered [21]. A recent study in The Gambia showed that INFc
responses to one of the key MTBC antigens differed in an MTBC
lineage–specific manner [63]. Developing a universally effective
vaccine might be the only way to eliminate TB in the future [3].
This is particularly true given the large reservoir of latently
infected individuals in the world, which would be impossible to
eliminate through prophylactic drug treatment. Considering that
natural TB infection does not protect against exogenous
reinfection and disease, however, mimicking natural infection
using attenuated strains or a cocktail of traditional INFc-inducing
antigens might not necessarily be the most promising vaccine
strategy. Indeed, the largely unsuccessful implementation of BCG
vaccination might serve as a warning [64].
Acknowledgments
We thank Peter Small and Douglas Young for comments on the
manuscript.
References
1. World Health Organization (2009) Global tuberculosis control - surveillance,
planning, financing. Geneva, Switzerland: WHO.
2. Stop TB Partnership (2006) The global plan to stop TB 2006–2015. Geneva:
WHO.
3. Young DB, Perkins MD, Duncan K, Barry CE (2008) Confronting the scientific
obstacles to global control of tuberculosis. J Clin Invest 118: 1255–1265.
4. Kaufmann SH, Parida SK (2007) Changing funding patterns in tuberculosis.
Nat Med 13: 299–303.
5. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA (1995) Tuberculosis in
New York City–turning the tide. N Engl J Med 333: 229–233.
6. Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, et al. (1997)
Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex
indicates evolutionarily recent global dissemination. Proc Natl Acad Sci U S A
94: 9869–9874.
7. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, et al. (1993)
Strain identification of Mycobacterium tuberculosis by DNA fingerprinting:
recommendations for a standardized methodology. J Clin Microbiol 31:
406–409.
8. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, et al. (1994) The
epidemiology of tuberculosis in San Francisco. A population-based study using
conventional and molecular methods. N Engl J Med 330: 1703–1709.
9. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, et al. (1993)
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in
patients with advanced HIV infection. N Engl J Med 328: 1137–1144.
10. Mathema B, Kurepina NE, Bifani PJ, Kreiswirth BN (2006) Molecular
epidemiology of tuberculosis: current insights. Clin Microbiol Rev 19: 658–685.
11. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. (1998) Deciphering
the biology of Mycobacterium tuberculosis from the complete genome sequence.
Nature 393: 537–544.
12. Tsolaki AG, Hirsh AE, DeRiemer K, Enciso JA, Wong MZ, et al. (2004)
Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from
genomic deletions in 100 strains. Proc Natl Acad Sci U S A 101: 4865–4870.
13. Kato-Maeda M, Rhee JT, Gingeras TR, Salamon H, Drenkow J, et al. (2001)
Comparing genomes within the species Mycobacterium tuberculosis. Genome Res
11: 547–554.
14. Nicol MP, Wilkinson RJ (2008) The clinical consequences of strain diversity in
Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 102: 955–65.
15. Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW, Small PM (2004) Stable
association between strains of Mycobacterium tuberculosis and their human host
populations. Proc Natl Acad Sci U S A 101: 4871–4876.
16. Supply P, Warren RM, Banuls AL, Lesjean S, Van Der Spuy GD, et al. (2003)
Linkage disequilibrium between minisatellite loci supports clonal evolution of
Mycobacterium tuberculosis in a high tuberculosis incidence area. Mol Microbiol 47:
529–538.
17. Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, et al. (2002) A
new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl
Acad Sci U S A 99: 3684–3689.
18. Mostowy S, Cousins D, Brinkman J, Aranaz A, Behr MA (2002) Genomic
deletions suggest a phylogeny for the Mycobacterium tuberculosis complex. J Infect
Dis 186: 74–80.
19. Reed MB, Pichler VK, McIntosh F, Mattia A, Fallow A, et al. (2009) Major
Mycobacterium tuberculosis lineages associate with patient country of origin. J Clin
Microbiol 47: 1119–28.
20. Gagneux S, Deriemer K, Van T, Kato-Maeda M, de Jong BC, et al. (2006)
Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad
Sci U S A 103: 2869–2873.
21. Gagneux S, Small PM (2007) Global phylogeography of Mycobacterium tuberculosis
and implications for tuberculosis product development. Lancet Infect Dis 7:
328–337.
22. Baker L, Brown T, Maiden MC, Drobniewski F (2004) Silent nucleotide
polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg Infect Dis
10: 1568–1577.
23. Gutacker MM, Mathema B, Soini H, Shashkina E, Kreiswirth BN, et al. (2006)
Single-nucleotide polymorphism-based population genetic analysis of Mycobac-
terium tuberculosis strains from 4 geographic sites. J Infect Dis 193: 121–128.
24. Filliol I, Motiwala AS, Cavatore M, Qi W, Hernando Hazbon M, et al. (2006)
Global phylogeny of Mycobacterium tuberculosis based on single nucleotide
polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic
accuracy of other DNA fingerprinting systems, and recommendations for a
minimal standard SNP set. J Bacteriol 188: 759–772.
25. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, et al. (2006)
Mycobacterium tuberculosis complex genetic diversity: mining the fourth interna-
tional spoligotyping database (SpolDB4) for classification, population genetics
and epidemiology. BMC Microbiol 6: 23.
26. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, et al. (1998) Multilocus
sequence typing: a portable approach to the identification of clones within
populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95:
3140–3145.
27. Maiden MC (2006) Multilocus sequence typing of bacteria. Annu Rev Microbiol
60: 561–588.
PLoS Pathogens | www.plospathogens.org 6 October 2009 | Volume 5 | Issue 10 | e100060028. Achtman M (2008) Evolution, population structure, and phylogeography of
genetically monomorphic bacterial pathogens. Annu Rev Microbiol 62: 53–70.
29. Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, et al. (2008) High
functional diversity in Mycobacterium tuberculosis driven by genetic drift and human
demography. PLoS Biol 6: e311.
30. Gutierrez C, Brisse S, Brosch R, Fabre M, Omais B, et al. (2005) Ancient origin
and gene mosaicism of the progenitor of Mycobacterium tuberculosis. PLoS
Pathogens 1: 1–7.
31. World Health Organization (2008) Anti-tuberculosis drug resistance in the world
report no. 4. Geneva, Switzerland: WHO.
32. Zak DE, Aderem A (2009) Systems biology of innate immunity. Immunol Rev
227: 264–282.
33. Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, et al. (2006) Systems biology
approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature
441: 173–178.
34. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, et al. (2009) Systems
biology approach predicts immunogenicity of the yellow fever vaccine in
humans. Nat Immunol 10: 116–125.
35. Stuart LM, Boulais J, Charriere GM, Hennessy EJ, Brunet S, et al. (2007) A
systems biology analysis of the Drosophila phagosome. Nature 445: 95–101.
36. Young D, Stark J, Kirschner D (2008) Systems biology of persistent infection:
tuberculosis as a case study. Nat Rev Microbiol 6: 520–8.
37. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, et al. (2009) A
replication clock for Mycobacterium tuberculosis. Nat Med 15: 211–4.
38. Young DB, Gideon HP, Wilkinson RJ (2009) Eliminating latent tuberculosis.
Trends Microbiol 17: 183–188.
39. Cohen T, Dye C, Colijn C, Murray M (2009) Mathematical models of the
epidemiology and control of drug-resistant TB. Expert Rev Resp Med in press.
40. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M (2009) Drivers of
tuberculosis epidemics: The role of risk factors and social determinants. Soc Sci
Med 68: 2240–6.
41. Borrell S, Gagneux S (2009) Infectiousness, reproductive fitness, and evolution of
drug-resistant Mycobactyerium tuberculosis. Int J Tuberc Lung Dis in press.
42. Dye C, Williams BG, Espinal MA, Raviglione MC (2002) Erasing the world’s
slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295:
2042–2046.
43. Bottger EC, Springer B, Pletschette M, Sander P (1998) Fitness of antibiotic-
resistant microorganisms and compensatory mutations. Nat Med 4: 1343–1344.
44. Gagneux S, Burgos MV, DeRiemer K, Encisco A, Munoz S, et al. (2006) Impact
of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium
tuberculosis. PLoS Pathog 2: e61.
45. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, et al. (2006) The
competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:
1944–1946.
46. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, et al.
(2000) Mutations at amino acid position 315 of the katG gene are associated with
high-level resistance to isoniazid, other drug resistance, and successful
transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 182:
1788–1790.
47. Cohen T, Murray M (2004) Modeling epidemics of multidrug-resistant M.
tuberculosis of heterogeneous fitness. Nat Med 10: 1117–1121.
48. Blower SM, Chou T (2004) Modeling the emergence of the ‘hot zones’:
tuberculosis and the amplification dynamics of drug resistance. Nat Med 10:
1111–1116.
49. Dye C (2009) Doomsday postponed? Preventing and reversing epidemics of
drug-resistant tuberculosis. Nat Rev Microbiol 7: 81–87.
50. Mardis ER (2008) Next-generation DNA sequencing methods. Annu Rev
Genomics Hum Genet 9: 387–402.
51. MacLean D, Jones JD, Studholme DJ (2009) Application of ‘next-generation’
sequencing technologies to microbial genetics. Nat Rev Microbiol 7: 287–296.
52. Hardy J, Singleton A (2009) Genomewide association studies and human
disease. N Engl J Med 360: 1759–1768.
53. Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, et al. (2009) The
genetic structure and history of Africans and African Americans. Science 324:
1035–44.
54. Basu A, Mukherjee N, Roy S, Sengupta S, Banerjee S, et al. (2003) Ethnic India:
a genomic view, with special reference to peopling and structure. Genome Res
13: 2277–2290.
55. Campbell MC, Tishkoff SA (2008) African Genetic Diversity: Implications for
human demographic history, modern human origins, and complex disease
mapping. Annu Rev Genomics Hum Genet 9: 403–33.
56. Goldstein DB (2009) Common genetic variation and human traits. N Engl J Med
360: 1696–1698.
57. Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for
transcriptomics. Nat Rev Genet 10: 57–63.
58. Arnvig KB, Young DB (2009) Identification of small RNAs in Mycobacterium
tuberculosis. Mol Microbiol 73: 397–408.
59. de Jong BC, Hill PC, Aiken A, Awine T, Antonio M, et al. (2008) Progression to
active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis
lineage in the Gambia. J Infect Dis 198: 1037–43.
60. Caws M, Thwaites G, Dunstan S, Hawn TR, Thi Ngoc Lan N, et al. (2008) The
influence of host and bacterial genotype on the development of disseminated
disease with Mycobacterium tuberculosis. PLoS Pathog 4: e1000034.
61. Thwaites G, Caws M, Chau TT, D’Sa A, Lan NT, et al. (2008) The relationship
between Mycobacterium tuberculosis genotype and the clinical phenotype of
pulmonary and meningeal tuberculosis. J Clin Microbiol 46: 1363–8.
62. Ernst JD, Lewinsohn DM, Behar S, Blythe M, Schlesinger LS, et al. (2007)
Meeting report: NIH workshop on the Tuberculosis Immune Epitope Database.
Tuberculosis (Edinb) 88: 366–70.
63. de Jong BC, Hill PC, Brookes RH, Gagneux S, Jeffries DJ, et al. (2006)
Mycobacterium africanum elicits an attenuated T Cell response to Early Secreted
Antigenic Target, 6 kDa, in patients with tuberculosis and their household
contacts. J Infect Dis 193: 1279–1286.
64. Andersen P, Doherty TM (2005) Opinion: The success and failure of BCG -
implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656–62.
PLoS Pathogens | www.plospathogens.org 7 October 2009 | Volume 5 | Issue 10 | e1000600